Tofacitinib is an orally available inhibitor of Janus kinases (JAK), with immunomodulatory and anti-inflammatory activities. Upon administration, tofacitinib binds to JAK and prevents the activation of the JAK-signal transducers and activators of transcription (STAT) signaling pathway. This may decrease the production of pro-inflammatory cytokines, such as interleukin (IL)-6, -7, -15, -21, interferon-alpha and -beta, and may prevent both an inflammatory response and the inflammation-induced damage caused by certain immunological diseases. JAK kinases are intracellular enzymes involved in signaling pathways affecting hematopoiesis, immunity and inflammation.
Tofacitinib is an oral, small molecule inhibitor of Janus kinases that is used to treat moderate-to-severe rheumatoid arthritis, psoriatic arthritis and inflammatory bowel disease. Tofacitinib is associated with transient and usually mild elevations in serum aminotransferase levels during therapy, but has yet to be linked to cases of clinically apparent acute liver injury.
Tofacitinib is a pyrrolopyrimidine that is pyrrolo[2,3-d]pyrimidine substituted at position 4 by an N-methyl,N-(1-cyanoacetyl-4-methylpiperidin-3-yl)amino moiety. Used as its citrate salt to treat moderately to severely active rheumatoid arthritis. It has a role as an EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor and an antirheumatic drug. It is a pyrrolopyrimidine, a N-acylpiperidine, a nitrile and a tertiary amino compound.
The chemical system of tofacitinib citrate is 3 - {(3R, 4R) - 4-methyl-3 - [methyl - (7H-pyrrolo [2,3-d] pyrimidin-4-yl) - piperidin-1-yl] - 3-oxo-propionitrile citrate. Chemical book is a Janus kinase inhibitor developed by Pfizer. On November 6, 2012, the US Food and Drug Administration (FDA) approved the substance as a drug on the market for the treatment of adult patients with moderate to severe active rheumatoid arthritis (RA) who do not respond or tolerate methotrexate.
Tofatib is suitable for adult patients with moderate to severe active rheumatoid arthritis (RA) who have insufficient or intolerable efficacy of methotrexate. It can be used in combination with methotrexate or other non biological anti rheumatic drugs (DMARD).
Tofatinib citrate is a drug for rheumatoid arthritis developed by Pfizer pharmaceutical company of the United States. It is used in adults with moderate to severe active rheumatoid arthritis (RA) who have insufficient or intolerable response to methotrexate. This product is a Janus kinase inhibitor, which is taken twice a day. On November 6, 2012, the food and Drug Administration (FDA) and Pfizer jointly announced that tofatinib citrate was approved for adult patients with moderate to severe active rheumatoid arthritis (RA) who had insufficient or intolerable response to methotrexate treatment. Xeljanz can be used as a single treatment or in combination with methotrexate or other nonbiological disease relief anti rheumatism drugs (DMARD). The drug should not be used in combination with biological DMARD or strong immunosuppressants such as azathioprine and cyclosporin. The approved dose of xeljanz was twice a day, 5mg per time. Seven clinical trials evaluated the safety and effectiveness of tofatinib citrate in adults with moderate to severe active rachemicalbook. In all trials, patients treated with xeljanz had significant improvement in clinical response and physical function compared to those who received placebo. In clinical trials, the most common adverse reactions were upper respiratory tract infection, headache, diarrhea, nasal congestion, throat pain and nasopharyngitis. The use of xeljanz is associated with increased risk of serious infection, including opportunistic infections, tuberculosis, cancer and lymphoma. The xeljanz product label contains framed warnings about these security risks. The treatment of xeljanz was also related to the increase of cholesterol and liver enzyme values and the decrease of blood cell count. To study the long-term effects of xeljanz on heart disease, cancer and severe infections, FDA requires a post market study that will assess two doses of xeljanz (tofatinib citrate) treatment and include it in a control group that received another approved treatment.
Our Tofacitinib API And Intermediates is as following,we have all the below API and intermedites offering all year.
Tofacitinib Intermediate Cas 3680-69-1,Tofacitinib Cas 3680-69-1
